Skip to main content
SpringerLink
Log in

The Future of Oral Hormonal Contraception

  • Chapter
Fertility Control — Update and Trends

  • 93 Accesses

Abstract

Each second, the world population increases by three newborn babies (98 million per year); nine out of ten are born in developing countries. In 2050, the total population will be 12.5 billion instead of the 6 billion of today. No war, no disease, but only access to and the acceptance of effective methods of fertility control can stop the growth of the world population. Additionally, religious aspects, the realisation of female rights, equal access to education and jobs for women and men, availability of pensions (no further need for support by a big family) will be the pillars of a successful family policy. Furthermore, a better health care system for women (500,000 deaths annually during pregnancy and childbirth) and safe techniques of pregnancy termination (200,000 deaths annually per 50 million abortions) are necessary. Oral hormonal contraceptives (OCs) are one of the methods of fertility control which is highly effective, safe, well accepted and available in most countries worldwide.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH (1994) Mutation in blood coagulation factor V associated with resistance to activated Protein C. Nature 369: 64–67

    Article  PubMed  CAS  Google Scholar 

  • Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Buller HR, Vandenbrouke JP (1995) Enhancement by factor V Leiden mutation of risk of deep vein thrombosis associated with oral contraceptives containing a third generation progestagen. Lancet 346: 1593–96

    Article  PubMed  CAS  Google Scholar 

  • Bonnar J, Daly L, Sabra A, Carroll A (1988) Effects of oral contraception on blood clotting. In: Runnebaum B, Rabe T, Kiesel L (eds) Female contraception, update and trends. Springer-Verlag, Berlin Heidelberg New York, pp 56–59

    Chapter  Google Scholar 

  • Bottinger LE, Boman G, Eklund G, Westerholm B (1980) Oral contraceptives and thromboembolic disease. Effects of lowering oestrogen content. Lancet i: 1097

    Google Scholar 

  • Bowes WA, Katta LR, Droegemueller W, Braight TG (1989) Triphasic randomized clinical trial. Comparison of effects on carbohydrate metabolism. Am J Obstet Gynecol 161: 1402

    Google Scholar 

  • Bradford-Hill (1965) Criteria of causality. Proceedings of the Royal Society of Medicine 58: 295–300

    Google Scholar 

  • Brosnihan KB, Moribuchi A, Nakamoto H, Dean RH, Ganten D, Ferrario CM (1994) Estrogen augments the contribution of nitric oxide to blood pressure regulation in transgenic hypertensive rats expressing the mouse Ren-2 gene. Am J Epidemiol 7: 576–582

    CAS  Google Scholar 

  • Casagrande JT, Pike MC, Ross RK, Louie EW, Roy S, Henderson BE (1979) Incessant ovulation and ovarian cancer. Lancet ii: 170–173

    Google Scholar 

  • Cates W Jr, Washington AE, Rubin GL, Peterson HB (1985) The pill, chlamydia and PID. Fam Plann Perspect 17: 175

    Article  PubMed  Google Scholar 

  • Centers for Disease Control (1983a) Oral contraceptive use and the risk of ovarian cancer. JAMA 249: 1596–1599

    Google Scholar 

  • Centers for Disease Control (1983a) The reduction in risk of ovarian cancer associated with oral contraceptive use. N Engl J Med 1987a 316: 650–655

    Google Scholar 

  • Centers for Disease Control (1987a) The reduction in risk of ovarian cancer associated with oral contraceptive use. N Engl J Med 1987a 316: 650–655

    Google Scholar 

  • Centers for Disease Control (1987b) Combination oral contraceptive use and the risk of endometrial cancer. Dominant social status and contraceptive hormone treatment inhibit atherogenesis in premenopausal monkeys. Arterioscler. Thromb. Vasc. Biol 15: 2094–2100

    Google Scholar 

  • Collaborative Group on Hormonal Factors in Breast Cancer (1996) Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 347: 1713–27

    Google Scholar 

  • Crane MG, Harris JJ, Winsor W (1971) Hypertension, oral contraceptive agents, and conjugated estrogens. Ann Intern Med 74: 13

    PubMed  CAS  Google Scholar 

  • Croft P, Hannaford PC (1989) Risk factors for acute myocardial infarction in women: evidence from the Royal College of General Practitioners’ oral contraception study. BMJ 298: 165–168

    Google Scholar 

  • Eschenbach DA, Harnisch JP, Holmes KK (1997) Pathogenesis of acute pelvic inflammatory disease: role of contraception and other risk factors. Am J Obstet Gynecol 128: 838

    Google Scholar 

  • Farmer RDT, Lawrenson RA, Kennedy JG, Hambleton IR (1997) Populations-based study of risk of venous thromboembolism associated with varis oral contraceptives. Lancet 349: 83–86

    Article  PubMed  CAS  Google Scholar 

  • Fathalla MF. Incessant ovulation-a factor in ovarian neoplasia? Lancet 1971; ii:163

    Google Scholar 

  • Fisch I, Frank J (1977) Oral contracptives and hypertension. JAMA 237: 2499–2503

    Google Scholar 

  • Fitzgerald C, Feichtinger W, Spona J, Elstein M, Lüdicke F, Müller U, Williams C (1994) Comparison of the effects of two monophasic low dose oral contraceptives on the inhibition of ovulation. Adv Contracept 10: 5–18

    Article  PubMed  CAS  Google Scholar 

  • Gaspard UJ, Lefebvre PJ (1990) Clinical aspects of the relationship between oral contraceptives, abnormalities in carbohydrate metabolism, and the development of cardiovascular disease. Am J Obstet Gynecol 163: 334

    PubMed  CAS  Google Scholar 

  • Gerstman BB, Piper JM, Tomita DK, Ferguson WJ, Stadel BV, Lundin FE (1991) Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 133: 32

    PubMed  CAS  Google Scholar 

  • Griffin JH, Evatt B, Widerman C, Fernandez JA (1993) Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood 82 1989–1993

    PubMed  CAS  Google Scholar 

  • Herings RCM, Boer A de, Urquhart J, Leufkens HGM (1996) Non-causal explanations for the increased risk of venous thromboembolism among users of third generation oral contraceptives. Pharmacoepidemiol Drug Safety 5:S 88

    Google Scholar 

  • Hille ET, Westendrop RG, Vandenbroucke JP, Rosendaal FR (1997) Mortality and causes of death in families with the factor V Leiden mutation (resistance to activated protein C). Blood 89: 1963–1967

    PubMed  CAS  Google Scholar 

  • Inman WHW, Vessey MP (1968) Investigation of deaths form pulmonary, coronary and cerebral thrombosis and embolism in women of child-bearing age. BMJ 2: 193–199

    Google Scholar 

  • Jick H, Jick SS, Gurevich V, Myers MW, Vasilakis C (1995) Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen compents. Lancet 348: 1589–1593

    Article  Google Scholar 

  • Jick H, Jick SS, Myers MW, Vasilakis C (1996) Risk of acute myocardial infarction and low-dose combined oral contraceptives. Lancet 347: 627–8

    Article  PubMed  CAS  Google Scholar 

  • Jordan WM (1961) Pulmonary embolism. Lancet 2 II: 1146–1147

    Google Scholar 

  • Kaplan JR, Adams MR, Anthony MS, Morgan TM, Manuck SB, Clarkson TB (1995) Dominant social status and contraceptive hormone treatment inhibit atherogenesis in premenopausal monkeys. Arterioscler Thromb Vasc Biol 15: 2094–2100

    Article  PubMed  CAS  Google Scholar 

  • Kierkegaard A (1980) Incidence of acute deep vein thrombosis in two districts. Acta Chir. Scand 146: 276–9

    Google Scholar 

  • Lewis MA, Heinemann, LAG, MacRae KD, Bruppacher R, Spitzer WO (1996a) Transnational Research Group on oral contraception and the health of young women. The increased risk of venous thromboembolism and the use of third generation progestagens; role of bias in observational research. Contraception 54: 5

    Google Scholar 

  • Lewis MA, Spitzer WO, Heinemann LA, MacRae KD, Bruppacher R, Thorogood M (1996b) Third generation oral contraceptives and risk of myocardial infarction: an international case-control study. BMJ 312: 88–90

    Google Scholar 

  • Lidegaard O, Edström B, Kreiner S (1997a) Oral contraceptives and venous thrombosis: a case-control study. Eur J Contracept Reprod Health Care 2: 73 (abstracts of the XV FIGO World Congress of Gynaecology and Obstetrics. Copenhagen, 3–8 August)

    Google Scholar 

  • Lidegaard O, Kreiner S (1997b) Cerebral thromboembolism and oral contraceptives: a case-control study. Abstract no 297 in 13th International Conference on Pharmacoepidemiology Orlando. Florida USA. August 1997 (submitted for publication)

    Google Scholar 

  • Lidegaard, O (1997c) Danish study on cardiovascular mortality. personal communication, OC-Symposium Madrid

    Google Scholar 

  • Meade TW, Greenburg G, Thompson SG (1980) Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50- and 30-µg estrogen preparations. BMJ 280: 1157

    Google Scholar 

  • Notelovitz M (1993) Oral contraceptives. Effect on hemostasis. In: Shoupe D, Haseltine FP (eds) Contraception. Springer-Verlag, Berlin Heidelberg New York, pp 42–59

    Google Scholar 

  • Nylander G, Olivecrona H (1976) The phlebographic pattern of acute leg thrombosis within a defined urban population. Acta Chir Scand 142: 505–511

    PubMed  CAS  Google Scholar 

  • Pabinger-Fasching I, Schneider B (1994) Thrombotic risk of women with hereditary antithrombin III-, protein C- and protein S-deficiency taking oral contraceptive medication. Thromb Haemost 71: 548552

    Google Scholar 

  • Panser LA, Phipps WR: Rees DC, Cox M, Clegg JB (1995) World distribution of factor V Leiden. Lancet 346: 1133–1134

    Google Scholar 

  • Peterson HB, Xia Hughes JM, Wilcox LS, Tylor LR, Trussell J (1996) The risk of pregnancy after tubal sterilization: findings from the U. S. Collaborative Review of Sterilization. Am J Obstet Gynecol 174: 1161–70

    Google Scholar 

  • Rabe T, Grunwald K, Kiesel L, Runnebaum B (1988) Oral contraceptives and lipid metabolism. In: Runnebaum B, Rabe T, Kiesel L (eds) Female contraception, update and trends, Springer-Verlag, Berlin Heidelberg New York, pp 64–90

    Chapter  Google Scholar 

  • Rabe T, Nitsche D, Runnebaum B (1997) The effects of monophasic and triphasic oral contraceptives on ovarian function and endometrial thickness. Eur J Contracept Reproduct Health Care 2: 39–51

    Article  CAS  Google Scholar 

  • Rabe T, Runnebaum B (1996) Kontrazeption. In: Runnebaum B., Rabe T (eds) Gynäkologische Endokrinologie und Fortpflanzungsmedizin. Springer, Berlin Heidelberg New York, pp 411–512

    Google Scholar 

  • Rabe T, Runnebaum B (1982) Kontrazeption. Springer, Berlin Heidelberg New York

    Google Scholar 

  • Redmond GP, Olson WH, Lippman JS, Kafrissen ME, Jones TM, Jorizzo JL (1997) Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial. Obstet Gynecol 89: 615–622

    Article  PubMed  CAS  Google Scholar 

  • Rees DC, Cox M, Clegg JB (1995) World distribution of factor V Leiden. Lancet 346: 11330–11340

    Google Scholar 

  • Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP (1995) Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 332: 912–917

    Article  PubMed  CAS  Google Scholar 

  • Rosenberg L, JRP, Lesko SM, Shapiro S (1990) Oral contraceptive use and the risk of myocardial infarction. Am J Epidemiol 131: 1009–1016

    PubMed  CAS  Google Scholar 

  • Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH (1995) High risk of thrombosis in patients homozygous for factor V Leiden ( Activated Protein C Resistance. Blood 85: 1504–1508

    Google Scholar 

  • Royal College of General Practitioners (1974) Oral contraception and health; an interim report from the oral contraception study of the Royal College of General Practitioners. Pitnam New York

    Google Scholar 

  • Runnebaum B, Rabe T, Kiesel L (eds) (1988) Female contraception, update and trends, Springer-Verlag, Berlin Heidelberg New York

    Google Scholar 

  • Runnebaum B, Rabe T, Kiesel L (eds) (1991) Female contraception and male fertility regulation, vol. 2. Parthenon, New York

    Google Scholar 

  • Skouby SO (1988) Effects of oral contraceptives on carbohydrate metabolism in healthy women. In: Runnebaum B, Rabe T, Kiesel L (eds) Female contraception, update and trends, Springer-Verlag, Berlin Heidelberg New York, pp 60–63

    Chapter  Google Scholar 

  • Speroff L, Darney P (eds) (1992) A clinical guide for contraception, Williams Wilkens, Baltimore

    Google Scholar 

  • Spitzer WO, Lewis MA, Heinemann LAJ, Thorogood M, MacRae KD (1996) Third generation oral contraceptives and risk of venous thromboembolic disorder: an international case-control study. BMJ 213: 83–8

    Google Scholar 

  • Spitzer WOS (1997) The 1995 pill scare revisited: anatomy of a non-epidemic. Hum Reprod 12: 2347–2357

    Article  PubMed  CAS  Google Scholar 

  • Spona J, Feichtinger W, Kindermann Ch, Wünsch C, Brill K (1996) Inhibition of ovulation by an oral contraceptive containing 100 ug Levonorgestrel in combination with 20 ug ethinylestradiol. Contraception 54: 299–304

    Article  PubMed  CAS  Google Scholar 

  • Stampfer MJ, Willett WC, Colditz GA, Speizer FE, Hennekens CH (1990) Past use of oral contraceptives and cardiovascular disease: a meta-analysis in the context of the Nurses’ Health Study. Am J Obstet Gynecol 163: 285–291

    PubMed  CAS  Google Scholar 

  • Sulssa S, Blair L, Spitzer WO, Cosson J, Lewis M, Heinemann LAJ (1997) First-time use of newer oral contraceptives and the risk of venous thromboembolism. Contraception 56: 141–6

    Article  Google Scholar 

  • The European Agency for the evaluation of medicinal products. Human Medicines Evaluation Unit (1997) Position statement of the CPMP on oral contraceptives containing desogestrel or gestodene. Press Release: Annex III to CPMP - Jan. 970

    Google Scholar 

  • Trussell J, Hatcher RA, Cates W Jr, Stewart FH, Kost K (1990) Contraceptive failure in the United States: an update, Stud Fam Plann 21: 51

    Article  PubMed  CAS  Google Scholar 

  • van der Vange N, Kloosterboer HJ, Haspels AA (1987) Effects of seven low-dose combined oral contraceptive preparations on carbohydrate metabolism. Am J Obstet Gynecol 156: 918

    PubMed  Google Scholar 

  • Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR (1994) Increased risk of venous thrombosis in oral-contraceptive users who carriers of factor V Leiden mutation. Lancet 344: 1453–1457

    Article  PubMed  CAS  Google Scholar 

  • Verwaltungsgericht: Der Präsident des Verwaltungsgerichts Berlin: Pressemitteilung. Grünes Licht für die Pille der dritten Generation. Beschlüsse der 14. Kammer des Verwaltungsgerichts Berlin (VG 14 A 360.97, VG 14 A 361.97, VG 14 A 379.97), 19. 12. 1997

    Google Scholar 

  • Vessey (1991a) An overview of the benefits and risks of combined oral contraceptives In: Runnebaum B., Rabe T, Kiesel L (eds) Female contraception and male fertility regulation, Parthenon, Lancester, England, pp 63–76

    Google Scholar 

  • Vessey (1991b) Oral contraceptives and cancer. In: Runnebaum B, Rabe T, Kiesel L (eds.): Female contraception and male fertility regulation, Parthenon, Lancester, England, pp 77–79

    Google Scholar 

  • Weir R, Briggs E, Mack A, et al. (1971) Blood pressure in women after one year of oral contraception. Lancet; 316: 467–470

    Article  Google Scholar 

  • Weir RJ, Wilson ESB, Cruikshank J, Tree N, Fraser R (1970) Effects on blood pressure of low dose oestrogen and progestagen only oral contraceptives. J Hypertens; 1 [Suppl 2]: 100

    Google Scholar 

  • WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception (1995) Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 346: 1582–1588

    Google Scholar 

  • WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception (1996a) Ischaemic stroke and combined oral contraceptives: results of an international, multi-centre, case-control study. Lancet; 348 (ii): 498–405 P

    Google Scholar 

  • WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception (1996b) Haemorrhagic stroke, overall stroke risk, and combined oral contraceptives: results of an international, multi-centre, case-control study. Lancet; 348 (ii): 505–510 P

    Google Scholar 

  • Wilcox AJ, Weinberg CR, Baird DD (1995) Timing of intercourse in relation to ovulation. Effects on the probability of conception, survival of pregnancy, and sex of the baby. N Engl J Med 333: 1517–1521

    Google Scholar 

  • Witt I, Kraus M (1996) APC-Resistenz: Klinik, Pathophysiologie and Diagnostik. Hämostaseologie 16: 60–75

    Google Scholar 

Download references

Authors
  1. Thomas Rabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Benno Runnebaum
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Rabe, T., Runnebaum, B. (1999). The Future of Oral Hormonal Contraception. In: Fertility Control — Update and Trends. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-86696-8_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-86696-8_4

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-86698-2

  • Online ISBN: 978-3-642-86696-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation